BD Ultra-Fine™ Nano™ Pen Needles

63% of people with diabetes are using the same needle length they started on at diagnosis.1

Research no longer supports the recommendation of long needles.1,2

Introducing BD Ultra-Fine™ Nano™ 4mm Pen Needles with Pentapoint™ comfort and EasyFlow™ technology.

EasyFlow Technology

EasyFlow™ Technology

BD Nano™ 4mm Pen Needles now with Extra Thin Wall Technology improves the insulin flow through the needle, making injections more convenient, including for people with hand-strength challenges.5

PentaPoint™ Comfort

BD Nano™ 4mm Pen Needles are the first and only pen needles with patented 5-bevel technology. The flatter, thinner needle tip eases into the skin with less force, clinically demonstrated to reduce the pain of injection.4

Optimal Injection Technique

You can use a simple, one-handed injection for all injection sites: arms, thighs, abdomen and buttocks. 

Compatibility

Compatible with all pen injectors for diabetes treatment.

Our smallest pen needle yet

BD's smallest, thinnest pen needle.


Less effort

EasyFlow™ Technology for less effort to inject


Patented comfort needle tips

PentaPoint™ Comfort for a smoother, gentler injection experience


100% Compatibility

100% compatibility guaranteed with all insulin and GLP-1 pens in Canada*


BD Nano™ 4mm supports optimal injection technique.

The body is covered with skin. Underneath the skin there's a layer of fat (subcutaneous tissue). Below that is a layer of muscle.

Average skin thickness ranges from 1.6 - 2.4 mm within the four most common injection sites.6,7To be absorbed properly, insulin or GLP-1 needs to be injected into the subcutaneous tissue layer, just under the skin. If the needle goes deeper, the dose may go into the muscle.

An injection into your muscle will likely hurt and speed up your insulin absorption which can cause a low blood sugar.The preferred areas used for injection are your adomen, thighs and buttocks. The back of your arm may also be used. Being small has it's advantages. In addition to increased comfort when using a 4 mm pen needle, you don't need to perform a skin lift in order to achieve a subcutaneous injection.* You can use a simple, one-handed injection for all injection sites: arms, thighs, abdomen and buttocks. Talk to your doctor or diabetes educator about the sites that are best for you.

Related Products

Nano Sample Order Form

If you would like to receive a free sample pack of 5 pen needles, please complete this form.

Order Now

Important Note

Not all products or therapies are approved in Canada. Please consult your local health care provider in Canada.

Note

*small children and extremely lean people with diabetes may require a skin lift

References
  1. De Coninck C, et al. Results and analysis of the 2008-2009 Insulin Injection Technique Questionnaire Survey. J Diabetes 2010;2(3):168-79.
  2. Berard L, Desrochers F, Husband A, MacNeill G, Roscoe R. Forum for Injection Technique (FIT) Canada – Recommendations for Best Practice in Injection Technique. 2011.
  3. Hirsch LJ, et al. Comparative glycemic control, safety and patient ratings for a new 4mm x 32G insulin pen needle in adults with diabetes. Current Medical Research Opinion 2010; 26(6):1531-41.
  4. Hirsch LJ, et al. Impact of a Modified Needle Tip Geometry on Penetration Force as well as Acceptability, Preference, and Perceived Pain in Subjects with Diabetes. Journal of Diabetes Science and Technology 2012;6(2):328-35
  5. Aronson R, et al. Insulin pen needles: Effects of extra thin-wall needle technology on preference, confidence, and other patient ratings. Clinical Therapeutics, In Press, Corrected Proof, Available online 20-Jun-2013.
  6. Gibney MA, et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Current Medical Research Opinion 2010;26(6):1519–30.
  7. Lo Presti D, et al. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatric Diabetes 2012;13(7):525-53.